

- 25 Cambridge, MA, USA.
- ⁸ School of Engineering Sciences in Chemistry, Biotechnology and Health, Royal
- 27 Institute of Technology (KTH), Stockholm, Sweden
- 28 ⁹ Bioinformatics Institute, Macrogen Inc., Seoul, Republic of Korea.
- 29 ¹⁰ Asian Genome Institute, Seoul National University Bundang Hospital, Gyeonggi-do,
- 30 Republic of Korea.
- ¹¹ 31 Department of Genome Analysis, Institute of Biomedical Science, Kansai Medical
- 32 University, Hirakata, Japan.
- 33 ¹² Human Disease Genomics, Center for Genomic Medicine, Kyoto University
- 34 Graduate School of Medicine, Kyoto, Japan.
- 13 35 Medical Genome Center, Research Institute, National Center for Geriatrics and
- 36 Gerontology, Obu, Japan.
- ¹⁴ Department of Public Health, Chiba University Graduate School of Medicine, Chiba,

38 Japan.

- ¹⁵ 39 Department of Computational Biology and Medical Science, Graduate School of
- 40 Frontier Sciences, The University of Tokyo, Tokyo, Japan.
- ¹⁶ Laboratory of Complex Trait Genomics, Department of Computational Biology and
- 42 Medical Sciences, Graduate School of Frontier Sciences, The University of Tokyo,
- 43 Tokyo, Japan.
- ¹⁷ Laboratory for Statistical and Translational Genetics, RIKEN Center for Integrative
- 45 Medical Science, Yokohama, Japan
- ¹⁸ 46 International University of Health and Welfare, Tokyo, Japan
- ¹⁹ Department of Frontier Cardiovascular Science, Graduate School of Medicine, The
- 48 University of Tokyo, Tokyo, Japan

49

50

- 52 kaoru.ito@riken.jp (K.I.)
- 53 mpsnyder@stanford.edu (M.S.)
- 54 komuro-tky@umin.ac.jp (I.K.)

56 **Summary**

57 Genome-wide association studies (GWASs) have advanced our understanding of 58 coronary artery disease (CAD) genetics and enabled the development of polygenic risk 59 scores (PRSs) for estimating genetic risk based on common variant burden. However, 60 GWASs have limitations in analyzing rare variants due to insufficient statistical power, 61 thereby constraining PRS performance. Here, we conducted whole genome sequencing 62 of 1,752 Japanese CAD patients and 3,019 controls, applying a machine learning-based 63 rare variant analytic framework. This approach identified 59 CAD-related genes, 64 including known causal genes like *LDLR* and those not previously captured by GWASs. 65 A rare variant-based risk score (RVS) derived from the framework significantly 66 predicted CAD cases and cardiovascular mortality in an independent cohort. Notably, 67 combining the RVS with traditional PRS improved CAD prediction compared to PRS 68 alone (area under the curve, 0.66 vs 0.61; p=0.007). Our analyses reinforce the value of 69 incorporating rare variant information, highlighting the potential for more 70 comprehensive genetic assessment.

71

72 **Keywords**

73 Coronary artery disease; Rare variants; Genetic risk estimation; Polygenic risk 74 score; Myocardial infarction; Genome-wide association study; Machine learning; 75 BioBank Japan

76

77

79 **Introduction**

80 Despite advancements in treatments and medications, coronary artery disease 81 (CAD), encompassing conditions such as angina pectoris and myocardial infarction 82 (MI), remains a leading cause of death worldwide 1,2 . CAD etiology is complex, 83 involving a multifaceted interplay between genetic predisposition and environmental 84 determinants. Lifestyle factors including diet, smoking, and physical activity are well-85 established contributors to the onset and progression of CAD ^{3,4}. Additionally, 86 conditions such as elevated low-density lipoprotein (LDL) cholesterol, hypertension, 87 and glucose intolerance further exacerbate the risk profile $⁵$. The importance of genetic</sup> 88 predisposition is also underscored by a European twin study, which estimated that 89 genetic factors contributed to over 50% of CAD development 6.7 . Therefore, 90 understanding the genetic underpinnings of CAD and accurately estimating an 91 individual's lifetime genetic risk are crucial for effective prevention and management 92 strategies.

93 To date, genome-wide association studies (GWASs) and their meta-analyses 94 have identified more than 300 loci associated with CAD $8-12$. Polygenic risk scores 95 (PRSs) derived from GWAS summary statistics have enabled the estimation of 96 individual-level CAD risk $13,14$. However, despite these significant advancements, the 97 heritability of CAD explained by GWASs remains lower than anticipated. This gap 98 may be partly attributed to the primary focus of GWAS on low frequency to common 99 variants, while rare variants are often underrepresented in these analyses $5,15$. Rare 100 variants often have a large effect size on diseases and phenotypes, making them a 101 promising target for drug development 16 . Incorporating rare variants into genetic risk 102 scores could significantly enhance the accuracy of CAD prediction. Despite this

103 potential, previous GWASs and aggregated rare variant association analyses have 104 struggled even in large-scale sequencing studies, identifying only a few genes at exome-105 wide significance per trait $17,18$. Furthermore, calculating a genetic risk score based on 106 rare variants is challenging because gene-level effect sizes are not estimated by 107 conventional gene-based analysis methods.

108 Recently, advancements in machine learning have led to the development of 109 novel methods for genetic analysis, one of which is the HEAL (Hierarchical Estimate 110 from Agnostic Learning) method, a machine learning-based framework for 111 comprehensive rare variant analysis. This approach has been successful in identifying 112 disease-associated genes and creating genetic risk scores in patients with abdominal 113 aortic aneurysm¹⁹. In the current study, we conducted whole genome sequencing 114 (WGS) of Japanese CAD patients and applied a modified version of the HEAL 115 framework tailored for CAD to analyze rare variants and systematically prioritize 116 disease-associated genes. Furthermore, we developed a rare variant-based genetic risk 117 score (RVS) using this framework and validated the performance with an independent 118 cohort. We then explored the relationship between the RVS and GWAS-based PRS to 119 elucidate the characteristics of rare variants in CAD, bridging the gap in our 120 understanding of CAD genetics by incorporating rare variant information, potentially 121 uncovering novel insights into disease mechanisms and improving risk prediction 122 models.

123 **Results**

124 **Whole genome sequencing of CAD samples in the Japanese population**

125 The overview and the design of our study are shown in **Figure 1**. We 126 performed WGS on the discovery cohort comprising 1,765 Japanese CAD patients and 127 3,148 controls. In order to enhance the genetic discovery power ²⁰, we prioritized 128 patients with early-onset MI, a severe form of CAD, from the BioBank Japan (BBJ) 129 cohort. The average age of MI onset in these patients was 47.4 ± 4.1 years, indicating a 130 relatively young population with a severe disease phenotype. After quality control of the 131 WGS data, we retained 4,771 individuals (1752 cases and 3019 controls) with 132 51,717,580 genetic variants. For the validation WGS cohort, we included 200 CAD 133 cases and 824 control samples with 25,531,471 variants (**Table S1 and S2**). 134 Demographic features in each cohort are summarized in **Table 1**. We then used the 135 quality-controlled data for further analyses including single variant association tests to 136 identify individual variants associated with CAD, a conventional gene-based association 137 test to examine the cumulative effect of variants within specific genes, and a machine 138 learning-based framework to uncover the potential contribution of rare variants (**Figure** 139 **S1**).

140 We first conducted a single variant association test in the discovery cohort 141 using a logistic regression model implemented in PLINK software with covariates of 142 age, sex and top ten ancestry principal components (PCs). The genomic inflation factor 143 λ_{GC} was calculated to be 1.03, indicating minimal inflation of test statistics and 144 suggesting that the quality control applied to the samples was adequate (**Figure S2**). 145 This initial single variant association analysis did not identify any genetic loci that 146 reached a genome-wide significance threshold of $P = 5 * 10^{-8}$. A subsequent analysis

147 was performed using SAIGE software designed to handle both common and rare 148 variants, adjusted for age, sex and top ten ancestry PCs. This analysis revealed two 149 previously reported loci on chromosome 12 that reached a genome-wide significance 150 threshold (rs7977233; p=1.47 $*$ 10⁻⁸, rs3782886; p=1.47 $*$ 10⁻⁸, respectively, (**Figure S3** 151 **and Table S3**)^{10,11}. However, these were both common variants, emphasizing the 152 difficulty in analyzing rare variants using current GWAS approaches.

153 To increase the detection power of rare variant associations, gene-based tests 154 are often used, in which variants are aggregated and analyzed together for each gene. 155 This approach allows for the analysis of rare variants that are underpowered in single 156 variant association tests due to their low frequency. It also increases detection power by 157 reducing the multiple testing burden. Thus, we conducted a gene-based rare variant 158 aggregated association analysis using the sequential kernel association test-optimal 159 (SKAT-O). While no genomic inflation was observed $(\lambda = 0.939)$ (**Figure S4**), the 160 *LDLR* gene surpassed a suggestive threshold ($p = 2.3 \times 10^{-5}$). However, no genes reached 161 the gene-wide significance threshold of $p = 2.5 \times 10^{-6}$ (**Figure S4 and Table S4**). This 162 result also highlighted the challenges of analyzing rare variants in genetic association 163 studies due to insufficient statistical power with a limited sample size.

164

165 **The machine learning-based framework prioritizes disease-associated genes and** 166 **reveals molecular networks**

167 We next conducted a machine learning-based rare variant analysis using a 168 modified HEAL 19 . In this framework, we first quantified the mutation burden for each 169 gene in each participant defined by the cumulative effects of deleterious 170 nonsynonymous variants within the gene. We then trained a penalized logistic

171 regression model to predict disease status based on these mutation burden scores. The 172 model was trained to identify a minimal set of most distinguishing features (genes) for 173 CAD, while also optimizing parameters for accurate disease prediction. Through robust 174 cross-validation (**Figure S5**), we successfully prioritized fifty-nine candidate genes 175 associated with CAD development (**Table S5, S6 and Figure S6)**.

176 To investigate the functions of the fifty-nine HEAL_{CAD} genes, we assessed 177 constraint scores and checked for overlaps with neighboring genes identified in previous 178 GWASs on CAD and its risk factors. Using the Genehancer database 21 , which provides 179 information on genome-wide enhancers and their target genes, we identified prioritized 180 genes that overlapped with the target genes of enhancers found significant in previous 181 GWASs. We also referenced the International Mouse Phenotyping Consortium (IMPC) 182 22 database to investigate the phenotypes associated with a gene knockout (KO) in mice 183 and conducted gene set enrichment analysis to identify functional clusters among the 184 HEAL_{CAD} genes. The genes were subsequently categorized into eight distinct clusters 185 based on the hierarchical clustering of their functional annotations (**Figure 2A, 2B and** 186 **Table S7**).

187 Among these clusters, cluster 3 notably included the *LDLR* gene, which 188 exhibited the strongest contribution to CAD. *LDLR* is a well-established causal gene for 189 familial hypercholesterolemia 23 and has been consistently associated with CAD in 190 previous GWASs and genome sequencing studies $9,24,25$, supporting the validity of our 191 machine learning-based framework. In the IMPC database, *LDLR* KO mice showed 192 increased circulating cholesterol levels 26 , a known risk factor for CAD. Cluster 7 193 contained genes related to obesity and metabolic processes, such as the *RNF216* locus, 194 which is associated with body mass index (BMI)^{27} and increased glucose levels in KO

195 mice ²². Additionally, the *VRK2* locus has been reported to be associated with BMI 28 , 196 smoking behavior and alcohol use 29 , indicating its broader impact on metabolic health. 197 Cluster 2 comprised genes identified by previous GWAS on phenotypes such as blood 198 pressure, diabetes, and cholesterol levels. The *FTO* gene within this cluster was 199 highlighted for its strong association with obesity $30,31$ and related phenotypes linked to 200 BMI 32 , LDL cholesterol 33 , blood pressure 34 , and CAD 35 . Cluster 8 encompassed 201 genes associated with cholesterol levels, obesity and blood pressure in GWAS and 202 GeneHancer categories, with phenotypic evidence in human and KO mice. For instance, 203 the *CYP27A1* locus is associated with diastolic blood pressure ³⁶ and triglyceride levels 204 37 and has connections to cholesterol levels and premature CAD according to human 205 phenotype ontology 38 .

206 To further determine the functions of the fifty-nine genes, we mapped them 207 onto the human protein-protein interaction (PPI) network followed by identifying 208 proteins that were tightly clustered with these HEAL_{CAD} genes as topological modules 209 19 . We identified 46 tightly clustered topological modules encompassing the HEAL_{CAD} 210 genes. Gene ontology analysis confirmed the functional coherence of the proteins 211 within each module, revealing significant enrichment for specific biological processes. 212 For instance, module M119 was significantly enriched for lipid homeostasis with a false 213 discovery rate (FDR) of $2.53*10^{-22}$, suggesting a critical role in regulating lipid levels 214 (**Figure 2C and Table S8**). These modules included pathways known as CAD risk 215 factors, such as lipid and glucose metabolism (M25, M31, M51, M86, M119). Notably, 216 M119 included lipid metabolism-related genes such as *LDLR*, *PCSK9*, *LIPA,* and 217 *ANGPTL3* (**Figure 2D**), which are well-known targets for medications treating 218 dyslipidemia and CAD $39\frac{40}{2}$. Other modules were associated with different biological

219 processes, including platelet volume (e.g., M13), immune system function (M1), blood 220 vessel and heart development (e.g., M47, M328), and RNA metabolism and translation 221 processes (e.g., M3, M34). While recent studies have indicated the contribution of 222 common variants identified by CAD-GWAS to the disease through various pathways 223 such as plaque formation, inflammation, transcriptional regulation, and angiogenesis 41 , 224 our findings suggest that diverse biological processes are also implicated in CAD, even 225 in the context of rare variants. This underscores the complexity of CAD pathogenesis, 226 involving a wide array of biological pathways and molecular mechanisms.

227

228 **Rare variant risk-based risk score and its clinical impact**

229 In conjunction with the prioritization of disease-related genes, the modified 230 HEAL enabled us to develop a prediction model for CAD based on genetic information. 231 Using the optimized machine learning model, we computed a rare variant-based risk 232 score (RVS) for each individual. The RVS demonstrated a significant predictive 233 capability for CAD, with an area under the receiver operating characteristics curve 234 (AUROC) of 0.574, as validated through a nested cross-validation approach in the 235 discovery cohort. When applied to an independent validation cohort, the RVS also 236 identified CAD cases with an AUROC of 0.581 ($p = 0.002$), indicating its ability to 237 discriminate CAD cases.

238 To further understand the characteristics of RVS in terms of clinical aspects, 239 we explored the association of RVS with clinically relevant parameters. The RVS 240 showed significant correlations with several key clinical measurements, including low-241 density-lipoprotein cholesterol (LDLC), total bilirubin (TBil), alanine aminotransferase 242 (ALT), prothrombin time (PT-INR), total cholesterol levels, neutrophil count, and

243 potassium levels (**Figure 3A and Table S9**). These correlations are noteworthy since 244 elevated cholesterol levels and coagulation abnormalities are established risk factors for 245 . CAD $42-44$. Moreover, alterations of total bilirubin and AST were also reported to be 246 associated with cardiovascular risk $45,46$, reinforcing the clinical relevance of the RVS in 247 the context of CAD.

248 We extended our analysis to assess the impact of the RVS on long-term 249 cardiovascular mortality. In the validation cohort, a higher RVS was significantly 250 associated with increased cardiovascular mortality (P = 0.01, log-rank test) (**Figure 3B)**. 251 When exclusively analyzing CAD patients, those with higher RVS also exhibited a 252 significantly worse cardiovascular mortality rate (p = 0.03, log-rank test) (**Figure 3C**). 253 These findings suggest that RVS not only predicts CAD occurrence but also correlates 254 with the disease severity and its long-term prognosis, highlighting its potential clinical 255 utility in risk stratification and prognosis estimation for CAD patients.

256

257 **The integration of RVS and PRS improves the performance of the genomic risk** 258 **score**

259 Many GWASs have been conducted for CAD, leading to the development of 260 PRS that primarily comprise common variants to predict the risk of CAD. Multiple 261 studies have reported that PRS can serve as an important indicator for predicting and 262 assessing the severity of CAD. Whereas these scores typically focus on common 263 variants and do not account for rare variants, which can also significantly contribute to 264 disease risk, our RVS encompasses rare variants not included in PRS. Thus, to compare 265 the properties between RVS and PRS, we first calculated individual PRS based on 266 CAD-GWAS¹¹ in the validation cohort. The PRS also significantly predicted CAD with

267 an AUROC of 0.61 (p = 0.001; 95% confidence interval (C.I.), 0.565-0.653). 268 Interestingly, there was no significant correlation between PRS and RVS ($r = -0.01$, $p =$ 269 0.73) (**Figure 4A**), indicating that RVS provides a different genomic perspective on 270 CAD risk.

271 When examining CAD cases specifically, RVS showed a negative correlation 272 with PRS $(r = -0.17, p = 0.015)$ (Figure 4A). Additionally, PRS was associated with 273 different clinical measurements compared to RVS, such as triglycerides, uric acid, body 274 mass index (BMI), and activated partial thromboplastin time (APTT) and it was 275 negatively associated with HDL cholesterol (HDLC), which is considered protective 276 against CAD (**Figure 3A, Figure S7 and Table S10**)⁴⁷. These data support the notion 277 that PRS and RVS may have complementary rather than redundant roles in predicting 278 CAD, as they were associated with different clinical parameters and did not show a 279 positive correlation.

280 Given these distinct properties, we integrated PRS and RVS to develop a 281 combined risk score (CRS) aiming at enhancement of the performance of the 282 framework in predicting CAD. The CRS showed positive correlations with several 283 clinical measures, including serum urinary acid, coagulation functions, LDLC, and 284 triglycerides (TG), while negatively correlating with HDLC levels (**Figure 4B and** 285 **Table S11**). Focusing on lipid metrics, CRS demonstrated correlations with LDLC, TC, 286 TG, and HDLC, suggesting that it combines the unique predictive elements of both RVS 287 and PRS (**Figure 4C**). Finally, we evaluated the predictive performance of CRS and 288 observed a significant improvement in CAD prediction compared to PRS alone in the 289 validation cohort (AUROC 0.66 vs 0.61, p=0.007; Pseudo R^2 0.093 vs 0.040, p = 290 0.0018; AUPRC 0.35 vs 0.29, p = 0.0154) (**Figure 5 and Table S12**). These results

- 291 suggest that RVS can complement PRS and that incorporating rare variant information
- 292 as an RVS into PRS significantly enhances the ability to predict CAD, thereby
- 293 addressing some of the unexplained heritability in the disease.

294

296 **Discussion**

297 In this study, we developed a machine learning-based analytical framework to 298 investigate the genetics of CAD pathogenesis with a focus on rare variants. We 299 leveraged this framework together with whole-genome sequencing (WGS) data from 300 the Japanese population to enhance our understanding of the complex CAD genetic 301 architecture. Our findings indicated that the modified HEAL, a machine learning-based 302 framework, effectively prioritized genes associated with CAD, including the well-303 established *LDLR* gene, while also uncovering intricate molecular networks involved in 304 the disease. The rare variant-based risk score (RVS) generated through this framework 305 demonstrated significant predictive power for CAD and long-term cardiovascular 306 mortality Furthermore, the RVS showed different characteristics from conventional 307 common variant-based PRS, and combining the rare variant-based RVS with the PRS 308 substantially improved CAD prediction.

309 Identifying disease-associated rare variants remains a significant challenge, 310 not only in single variant association analyses but also in aggregated rare variant 311 association analyses $48,49$. While some studies have adopted a targeted resequencing 312 approach by selecting specific genes based on prior knowledge 25,50 ; previous attempts 313 at genome-wide or exome-wide analyses have often suffered from insufficient statistical 314 power, leading to limited success in identifying previously uncharacterized genes 315 associated with complex traits like CAD 20 . Also in this study, the single variant 316 association analysis and the gene-based rare variant association analysis failed to reveal 317 genome-wide significant rare variants linked to CAD. Even in previous studies 318 involving more than 450,000 exome sequencing data from the UK biobank, only a 319 single gene, *LDLR*, reached a significance level in the gene-based test for CAD 17 .

320 These persistent challenges highlight the difficulties in rare variant analyses.

321 To address these challenges, we utilized a machine learning-based framework 322 to analyze rare variants, building on the HEAL model in a prior study, where Li et al. 323 successfully uncovered the genetic architecture of rare variants in abdominal aortic 324 aneurysm 19 . We adapted and optimized the model for CAD patients, marking the first 325 application of the technique in this disease context. Unlike the previous HEAL model 326 that focused only on missense single nucleotide variants (SNVs), our approach casts a 327 wider net as it incorporates insertion, deletion and putative loss-of-function (pLOF) 328 variants. This comprehensive inclusion of variant types allows for a more holistic 329 examination of the genetic landscape underlying CAD, potentially capturing a broader 330 spectrum of disease-associated genetic alterations. Furthermore, the robustness of our 331 model was enhanced by hyperparameter tuning through a grid search to avoid 332 overfitting and we evaluated its predictive performance using both internal cross-333 validation and an independent validation cohort 51 .

334 Through this improved framework, we successfully prioritized CAD-335 associated genes, extending beyond previously reported genes such as *LDLR*, *FTO,* and 336 *CYP27A1*. By mapping these genes onto the human protein-protein interaction network, 337 we uncovered 46 tightly clustered topological modules, providing insights into their 338 functional roles in CAD pathogenesis. Beyond lipid metabolism, the analysis revealed 339 modules associated with other relevant biological processes, including platelet function, 340 immune system regulation, blood vessel and heart development, and RNA metabolism. 341 Interestingly, while previous GWASs have highlighted the role of common variants in 342 CAD development through various pathways, our findings suggest that rare variants 343 also contribute to the disease through a wide spectrum of biological processes.

344 We also utilized our framework to develop an RVS and demonstrated its 345 discriminative capacity between CAD cases and controls in the validation cohort. The 346 distinctive feature of RVS lies in its utilization of rare nonsynonymous variants as input 347 data, setting it apart from conventional PRS that primarily focus on common variants. 348 This approach allows RVS to tap into a different spectrum of genomic information, 349 involving risk factors uncaptured by PRS. The independence of RVS from PRS is 350 further substantiated by the absence of a significant positive correlation between these 351 two scoring systems and the complementary relationships with clinical risk parameters. 352 This lack of correlation suggests that the RVS and PRS are capturing distinct aspects of 353 genetic risk for CAD, each contributing unique information to the overall risk 354 assessment. Importantly, the integration of RVS and PRS resulted in improved 355 predictive performance, demonstrating a synergistic effect that enhanced the ability to 356 accurately assess CAD risk. While methods combining information from one or a few 357 genetic mutations with PRS have been reported 52 , our study presented a more 358 comprehensive approach to combine rare and common variant information. 359 Furthermore, these findings reinforce the recognition that rare variants, despite their low 360 frequency, contribute significantly to the genetic architecture of CAD and can help 361 explain a portion of its missing heritability that common variants alone cannot account 362 for.

363 There are several limitations in the study. First, there was a difference in age 364 distribution between cases and controls. This discrepancy arose because we specifically 365 selected early-onset CAD patients for the case group, resulting in a younger average age. 366 As in previous rare variant studies, we prioritized selecting early-onset CAD cases to 367 enrich genetic contributions 2^0 . Second, some of the prioritized genes for CAD in this

368 study have unknown functions, especially in cluster 6. However, many loci and genes 369 identified in GWAS on CAD remain functionally uncharacterized, as well $41,53$. 370 Therefore, future research is necessary to investigate the gene function and biological 371 pathways to CAD development. Third, this study used WGS data from the Japanese 372 population, so it is not certain whether the RVS created in this study can be applied to 373 other populations since a PRS derived from GWAS in one population is reported to be 374 less accurate in other populations $11,54$. These results need to be validated in other 375 populations and prospective cohorts.

376 Taken together, our study underscores the important role of rare variants in the 377 genetic landscape of CAD. By leveraging a machine learning-based framework, we 378 have revealed CAD-associated genes and pathways influenced by rare variants. Our 379 results demonstrate the distinct and complementary value of RVS compared to 380 conventional PRS, highlighting the enhanced predictive power achieved through their 381 integration. This comprehensive approach offers new insights into the pathogenesis of 382 CAD, potentially leading to the accurate assessment and management of individual 383 CAD risk.

385 **Consortia**

386 **The Biobank Japan Project**

- 387 Koichi Matsuda^{1,2}, Takayuki Morisaki^{2,3}, Yukinori Okada⁴, Yoichiro Kamatani⁵, Kaori
- 388 Muto⁶, Akiko Nagai⁶, Yoji Sagiya², Natsuhiko Kumasaka⁷, Yoichi Furukawa⁸, Yuji
- 389 Yamanashi³, Yoshinori Murakami³, Yusuke Nakamura³, Wataru Obara⁹, Ken Yamaji¹⁰,
- 390 Kazuhisa Takahashi¹¹, Satoshi Asai^{12,13}, Yasuo Takahashi¹³, Shinichi Higashiue¹⁴, Shuzo
- 391 Kobayashi¹⁴, Hiroki Yamaguchi¹⁵, Yasunobu Nagata¹⁵, Satoshi Wakita¹⁵, Chikako Nito¹⁶,
- 392 Yu-ki Iwasaki¹⁷, Shigeo Murayama¹⁸, Kozo Yoshimori¹⁹, Yoshio Miki²⁰, Daisuke
- 393 Obata²¹, Masahiko Higashiyama²², Akihide Masumoto²³, Yoshinobu Koga²³ & Yukihiro
- 394 Koretsune²⁴
- 395
- 1.396 ^{1.} Laboratory of Genome Technology, Human Genome Center, Institute of Medical
- 397 Science, The University of Tokyo, Tokyo, Japan.
- 2 398 Laboratory of Clinical Genome Sequencing, Graduate School of Frontier Sciences,
- 399 The University of Tokyo, Tokyo, Japan.
- 300 3 The Institute of Medical Science, The University of Tokyo, Tokyo, Japan.
- 401 ⁴ Department of Genome Informatics, Graduate School of Medicine, The University of
- 402 Tokyo, Tokyo, Japan.
- ⁵ Laboratory of Complex Trait Genomics, Graduate School of Frontier Sciences, The
- 404 University of Tokyo, Tokyo, Japan.
- 6 405 Department of Public Policy, Institute of Medical Science, The University of Tokyo, 406 Tokyo, Japan.
- ⁷ Division of Digital Genomics, Institute of Medical Science, The University of Tokyo, 408 Tokyo, Japan.

- ⁸ Division of Clinical Genome Research, Institute of Medical Science, The University of
- 410 Tokyo, Tokyo, Japan.
- 911 Pepartment of Urology, Iwate Medical University, Iwate, Japan.
- ¹⁰ Department of Internal Medicine and Rheumatology, Juntendo University Graduate
- 413 School of Medicine, Tokyo, Japan.
- 11 414 Department of Respiratory Medicine, Juntendo University Graduate School of
- 415 Medicine, Tokyo, Japan.
- 12 416 Division of Pharmacology, Department of Biomedical Science, Nihon University
- 417 School of Medicine, Tokyo, Japan.
- 13 418 Division of Genomic Epidemiology and Clinical Trials, Clinical Trials Research
- 419 Center, Nihon University. School of Medicine, Tokyo, Japan.
- 14 420 Tokushukai Group, Tokyo, Japan.
- ¹⁵ Department of Hematology, Nippon Medical School, Tokyo, Japan.
- ¹⁶ Laboratory for Clinical Research, Collaborative Research Center, Nippon Medical
- 423 School, Tokyo, Japan.
- ¹⁷ Department of Cardiovascular Medicine, Nippon Medical School, Tokyo, Japan.
- ¹⁸ Tokyo Metropolitan Geriatric Hospital and Institute of Gerontology, Tokyo, Japan.
- 126 ¹⁹ Fukujuji Hospital, Japan Anti-Tuberculosis Association, Tokyo, Japan.
- 227 20 The Cancer Institute Hospital of the Japanese Foundation for Cancer Research, Tokyo,
- 428 Japan.
- 21 429 Center for Clinical Research and Advanced Medicine, Shiga University of Medical
- 430 Science, Shiga, Japan.
- ²² Department of General Thoracic Surgery, Osaka International Cancer Institute, Osaka,
- 432 Japan.

23 433 Iizuka Hospital, Fukuoka, Japan.

24 434 National Hospital Organization Osaka National Hospital, Osaka, Japan.

435

436 **Acknowledgements**

437 We thank the staff of BBJ and the Nagahama cohort study for their assistance 438 in collecting samples and clinical information. We thank the participants in the BBJ and 439 Nagahama cohort study for their contribution to the study. H.I. is funded by the Japan 440 Society for the Promotion of Science grant (JP22J00780, JP22K16128). K.I. is 441 supported by the Japan Agency for Medical Research and Development (AMED) under 442 grant numbers JP24bm1423005, JP24km0405209, JP24tm0524004, JP24tm0624002, 443 JP24km0405209 and JP24ek0210164. K.I. and K.O. are supported by the Research 444 Funding for Longevity Sciences from the NCGG (24–15). BBJ is supported by the 445 Tailor-Made Medical Treatment Program of the Ministry of Education, Culture, Sports, 446 Science, and Technology (MEXT) and AMED under grant numbers JP17km0305002 447 and JP17km0305001, JP.24tm0624002. The Nagahama study was supported by a JSPS 448 Grant-in-Aid for Scientific Research (C), KAKENHI grant numbers JP17K07255 and 449 JP17KT0125, and the Practical Research Project for Rare/Intractable Diseases from 450 AMED under grant numbers JP16ek0109070, JP18kk0205008, JP18kk0205001, 451 JP19ek0109283, and JP19ek0109348.

452

453 **Author contributions**

454 H.I. and K.I. conceived and designed the study. C.K., J.S., K.H., and F.M. 455 collected, managed and genotyped the Nagahama cohort. K.M., C.T. and Y.K. collected 456 and managed the BBJ samples. H.I. and K.I. analyzed WGS data, developed the

479 **Figure legends**

480 **Figure 1. Overview of the current study.**

481 We studied the genetic factors of coronary artery disease (CAD) combining whole-482 genome sequencing data and a machine learning-based framework named the modified 483 HEAL method in patients with MI, one of the most severe forms of CAD, and controls. 484 We sequenced the whole genomes of Japanese CAD patients and controls and applied 485 the modified HEAL method framework. The framework was based on a sparse 486 modeling devised to distinguish diseased individuals from controls. After the 487 hyperparameter tuning and training of the model by the cross-validation method, the 488 model outputted a list of genes related to CAD, which were subsequently analyzed by a 489 clustering-based method and mapped on the protein-protein interaction network to 490 reveal the CAD-associated modules. The function of the identified genes was also 491 confirmed by the human phenotype and knockout mouse phenotype databases. The 492 learned (optimized) machine learning model was applied to derive rare variant-based 493 genetic risk scores (RVS) to predict CAD outcomes in an independent validation cohort. 494 We also tested the relationship of the RVS with clinical features and common variant-495 based polygenic risk score (PRS). RVS was combined with PRS to improve the 496 prediction performance of CAD disease status in the independent validation cohort. BBJ, 497 BioBank Japan; MI, myocardial infarction; CRS, combined risk score

498

It is made available under a CC-BY-ND 4.0 International license. **(which was not certified by peer review)** is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. medRxiv preprint doi: [https://doi.org/10.1101/2024.08.13.24311909;](https://doi.org/10.1101/2024.08.13.24311909) this version posted August 13, 2024. The copyright holder for this preprint

500 **Figure 2. Functional analysis of HEAL_{CAD} genes**

501 (A) Fifty-nine genes identified by the machine learning-based framework were 502 annotated using six different criteria; 1) The constraint score (pLI) from the gnomAD 503 database 2) Overlap with GWAS on CAD and its risk factor (lipids, diabetes, obesity, 504 blood pressure, coagulation, smoking) phenotypes, 3) Overlap with the genes in which 505 GWAS-significant variants act as enhancers, 4) Knock-out mouse phenotype with blood 506 pressure, diabetes, and lipid traits, 5) Human phenotype ontology and 6) Gene ontology. 507 Then the fifty-nine genes were grouped into eight clusters by hierarchical clustering 508 based on functional annotations. For GWAS and Genehancer, red indicates a significant 509 association and light red denotes suggestive significance. (B) Gene ontology (GO) and 510 human phenotype ontology (HPO) term enrichment analysis. The GO and HPO 511 annotation results were based on 59 genes. Gene ontology categories included 512 molecular function, cellular components and biological process. GO and HPO 513 categories for each function were sorted by decreasing order of evidence based on the 514 GO enrichment test P-value. Only the significant categories after multiple test 515 corrections are shown. (C) The forty-six modules were identified in the protein-protein-516 interaction network using diffusion component analysis seeded by the 59 $HEAL_{CAD}$ 517 genes. (D) Visualization of the module 119 network of the protein-protein interactions. 518 The module included important genes involved in cholesterol metabolism, including 519 *LDLR*, *PCSK9*, *ANGPTL3*, *ANGPTL4*, and *LIPA*. GWAS, genome-wide association 520 study; CAD, coronary artery disease; DM, diabetes mellitus; BP, blood pressure; IMPC, 521 International Mouse Phenotyping Consortium; HP, human phenotype; GOMF, gene 522 ontology molecular function; GOBP, gene ontology biological pathway; GOCC, gene 523 ontology cellular component.

525 **Figure 3. Rare variant risk score (RVS) and its clinical impact**

526 (A) Correlation between RVS and continuous clinical indices. Data are presented as 527 Pearson's correlation coefficients and their 95% confidence intervals (CIs). Exact P 528 values are shown in Table S9. (B) Kaplan-Meier curves for cardiovascular mortality 529 among total participants stratified into two groups based on RVS. Participants with high 530 RVS died significantly earlier than those with low RVS. (C) Kaplan-Meier curves for 531 cardiovascular mortality among CAD patients (n=200) stratified into two groups based 532 on RVS. CAD patients with high RVS (top 5%) showed significantly worse 533 cardiovascular prognosis. LDLC, low-density lipoprotein cholesterol; Tbil, total 534 bilirubin; ALT, alanine aminotransferase; PTINR, prothrombin time international 535 normalized ratio; TC, total cholesterol; K, potassium; Hb, hemoglobin; UA, uric acid; 536 APTT, activated partial thromboplastin time; Alb, albumin; RBC, red blood cell; AST, 537 aspartate aminotransferase; WBC, white blood cell; CK, creatine kinase; TP, total 538 protein; Cre, creatinine; DBP, diastolic blood pressure; SBP, systolic blood pressure; 539 BUN, blood urea nitrogen; TG, triglycerides; CRP, C-reactive protein; PLT, platelet; P, 540 Phosphorus; γGTP, gamma-glutamyl transpeptidase; BS, blood sugar; LDH, Lactate 541 dehydrogenase.

542

544 **Figure 4. The Relationship between RVS, PRS, CRS, and clinical indices.**

563 **Figure 5. The combined RVS and PRS risk score improved CAD prediction**

564 (A) Receiver operating characteristic (ROC) curve for RVS, PRS and CRS (Combined 565 Risk Score). The curve plots the true positive rate (sensitivity) against the false positive 566 rate (1-specificity) for different threshold values of the predictive score. The area under 567 the curve (AUC) is indicated, representing the score's accuracy in predicting the 568 outcome. The dotted line represents a reference line of no discrimination (AUC = 0.5). 569 Points on the curve closer to the top-left corner indicate higher diagnostic accuracy. (B) 570 Precision-recall curve (PRC) for RVS, PRS and CRS. The curve shows the trade-off 571 between precision (positive predictive value) and recall (sensitivity) at various threshold 572 levels. The confidence interval for the area under the PRC was estimated from the 573 20,000 times bootstrap replication method. (C) Boxplot of Pseudo R^2 for CAD 574 prediction performance. This box plot displays the pseudo- R^2 values comparing the CAD prediction performance of RVS, PRS and CRS. The distribution of pseudo- R^2 was 576 estimated from 20,000 times bootstrapping. The box plot center line represents the 577 median, the bounds represent the first and third quartile, and the whiskers reach to 1.5 578 times the interquartile range.

579 **Tables**

580 **Table 1. Demographic features of participants**

581 **SD, standard deviation; BMI, body mass index; MI, myocardial infarction**

583 **STAR Methods**

584 **Code availability**

585 The code of the modified HEAL framework is available on 586 https://github.com/pirocv/HEAL.

587 **Study cohort**

588 Two previously described cohorts were used in the current study. BioBank 589 Japan (BBJ) is a hospital-based Japanese biobank project including clinical and genetic 590 data from a variety of patients $55,56$. Participants were recruited from 12 hospitals 591 throughout Japan. The Nagahama Prospective Genome Cohort (Nagahama study) is the 592 genome cohort conducted in Shiga, Japan. Participants aged 30–74 years were recruited 593 from the general population in Nagahama city from 2007 to 2010 57 .

594

595 **Whole genome sequencing and quality control**

596 We sequenced 1,765 CAD patients and 3,148 controls from the cohort. Whole 597 genome sequence (WGS) was performed on Illumina's HiSeqX aiming at 15x depth, 598 using 150-base pair-end reads. We also sequenced an additional 200 CAD cases and 836 599 controls aiming at 30x depth using 150-base paired-end reads. In order to enrich for a 600 genetic contribution to disease 20 , we prioritized patients with early-onset MI, one of the 601 most severe forms of CAD, within the BBJ cohort for WGS (age of MI onset in 15x and 602 30x WGS cohort: 47.4 ± 4.1 years and 36.0 ± 3.9 years, respectively). Sequenced reads 603 were aligned to the hs37d5 reference genome using BWA software 58 . The genotypes of 604 the samples were called using the HaplotypeCaller implemented in GATK v3.8. Per-605 sample Genomic Variant Call Format (gVCF) genotype data were merged and jointly 606 called using GenotypeGVCFs. We defined exclusion filters for genotypes as follows.

607 (1) For 15x depth data, filtered depth $(DP) < 2$, quality of the assigned genotype 608 (genotype quality; GQ) < 20. (2) For 30x depth data, DP < 5, GQ < 20, DP > 60 and GQ 609 < 95. We set these genotypes as missing and excluded variants with call rates < 90% 610 before variant quality score recalibration. For sample quality control, the following 611 samples were excluded: (1) age $\lt 20$ years old, (2) excess missing genotypes ($> 10\%$), 612 (3) samples whose genetically inferred sex did not match the self-reported sex, (4) 613 closely related samples estimated by identity-by-descent and identity-by-state analysis 614 (Pi-hat > 0.1875) and (5) excess heterozygosity. We also excluded non-Japanese 615 participants estimated from Principal component analysis (PCA) calculated using 616 PLINK 2.0 59 . The total number of genomes that failed data quality control is 617 summarized in **Table S13**. After the sample quality control, we retained 1,752 CAD 618 case samples and 3019 non-CAD control samples for 15x depth data and 200 case 619 samples and 824 control samples for 30x depth. Then, the variant quality control was 620 performed excluding (1) high missingness (5% for 15x depth and 1% for 30x depth), (2) 621 Hardy-Weinberg equilibrium ($P < 1$ *10⁻⁶), (3) variants in the low complexity region. 622 WGS data with 15x depth data was used as a discovery cohort and the 30x depth data 623 was used as the validation cohort in the machine learning-based analysis.

624

625 **Single variant association analysis**

626 The single variant association test was performed by logistic regression 627 implemented in PLINK 2.0^{60} with adjustment for age, sex, and the first 10 principal 628 components of ancestry. Principal components of ancestry were calculated using PLINK $2.0⁵⁹$. The inclusion of principal components as covariates in the logistic regression 630 analysis increases the power to detect true genetic associations and minimizes

631 confounding by population stratification 61 . Variants with a missing rate of less than 632 0.01 were included in the analysis. Genomic inflation factor $(\lambda_{\mathfrak{GC}})$ was calculated using 633 variants with MAF \geq 0.001. Single variant association analysis was also performed 634 using SAIGE 62 with adjustment for age, sex, and the first 10 principal components of 635 ancestry. SAIGE is widely used in GWASs for binary traits to account for population 636 structure and relatedness while correcting for the type I error rates 62 . The genome-wide 637 significance threshold was set at $P = 5 * 10^{-8}$. To define a locus, we added 500 kb to 638 both sides of each genome-wide significant SNP and merged overlapping regions. To 639 determine whether each locus was novel, a literature search was conducted to ascertain 640 if any of the regions contained SNPs had been previously reported as significant for 641 CAD.

642

643 **Aggregated rare variant association analysis**

644 We also performed gene-based association analysis using SAIGE-GENE+ 645 software, which accounts for the relatedness among the study samples $63,64$. We first 646 calculated sparse GRM using the WGS data and fit the null model in the SAIGE-647 GENE+ algorithm step1. For the gene-based association analysis, we extracted rare 648 (MAF < 0.001) nonsynonymous variants including (nonsynonymous single nucleotide 649 variations (SNV), nonframeshift insertion, nonframeshift deletion, frameshift insertion, 650 frameshift deletion, stopgain, stoploss, and splice site variants). Splice-site variants, 651 pLOF variants and damaging missense variants defined by a REVEL score > 0.5 ⁶⁵ were 652 included in the analysis. SKAT-O test implemented in SAIGE-GENE+ software was 653 performed with adjustment for age, sex and first 10 principal components of ancestry. 654 Gene-wide significance threshold and suggestive threshold were set at $P = 2.5 * 10^{-6}$

655 and $P = 5 * 10^{-4}$, respectively. Statistical inflation was estimated by O-O plot.

656

657 **Machine learning-based analysis (modified HEAL)**

658 We employed a recently developed machine learning-based rare variant 659 analysis method called HEAL (hierarchical estimate from agnostic learning). A detailed 660 HEAL method is described in the original paper 19 . In this framework (**Figure S8**), we 661 first annotated each variant using ANNOVAR software ⁶⁶ and extracted rare 662 nonsynonymous variants (nonsynonymous SNV, nonframeshift insertion, nonframeshift 663 deletion, frameshift insertion, frameshift deletion, stopgain, stoploss, and splice site 664 variants) that were not present in the East-Asian populations analyzed in the 1000 665 Genomes Project 67 . Variants with high frequency in the WGS data and gnomAD East 666 Asian database ⁶⁸ (MAF > 0.1) were also filtered. To estimate the mutation burden for 667 each gene based on the rare variants, we used the REVEL score (ranges from 0 to 1 with 668 a higher score indicating a damaging variant), which was internally computed by 669 ANNOVAR software. The deleteriousness score of the putative loss of function (pLOF) 670 variants, such as stopgain and splice site variants, was set as 1. Next, we calculated the 671 cumulative effects of rare nonsynonymous variants for each gene as

$$
g_{in} = \sum_{j=1}^{m_{in}} s_{ijn}
$$

672 , where g_{in} is the mutation burden of the gene *i* of *n*th sample, m_{in} is the number of rare 673 nonsynonymous variants, $s_{i,n}$ is the deleteriousness score for variant *j* of gene *i*. Using 674 the above formula, we obtained a matrix of estimated mutation burden for each gene per 675 sample $(x_n = (g_{1n}, g_{2n}, ..., g_{mn})$, where m is the number of the total genes). The 676 mutation burden was standardized (Z-score normalization). We trained a regularized

677 logistic regression model for a genome-based CAD prediction model. The input of the 678 model is the calculated mutation burden and the output is the probability of CAD as 679 shown in the following equation.

$$
\widehat{y_n} = P(y_n = 1 | \mathbf{x}_n) = \sigma(\mathbf{w}^T \mathbf{x}_n) = \frac{1}{1 + exp(-\mathbf{w}^T \mathbf{x}_n)}
$$

680, where y_n is the label for CAD case (1) or control (0), $\widehat{y_n}$ is the probability of being 681 CAD positive given the mutation burden x_n for the *n*th sample, σ is the sigmoid 682 function and w is the weight vector. To identify the optimal coefficient vector w that 683 achieve the maximum consistency between the model probabilities (\widehat{y}_n) and the 684 observations for the cohort (y_n) , we solved the following optimization problem.

$$
\min_{\mathbf{w}} -\frac{1}{N} \sum_{n=1}^{N} y_n \log \widehat{y_n} + (1 - y_n) \log (1 - \widehat{y_n}) + \lambda \big| |\mathbf{w}| \big|_1
$$

685 In this regularized logistic regression, regularization strength is determined by 686 parameter λ , and it is a hyperparameter of the machine learning model, which was 687 determined by the cross-validation method (**Figure S5**). By training the model to 688 predict disease status, it outputs the minimal set of most distinguishing features (genes) 689 for CAD. The trained model can be used to estimate the rare variant-based disease risk 690 score (RVS) from the genomic data. We have named this the modified HEAL because 691 our approach differs from the original method in that we included not only missense 692 variants but also pLOF variants. We determined the hyperparameters using grid search 693 and estimated the performance in the independent cohort to avoid bias and 694 overestimation of the model's performance, while the performance was estimated using 695 internal cross-validation in the original method.

697 **Interpretation of genes identified by modified HEAL**

698 To investigate the functions of the 59 identified genes, we first annotated each 699 one using various databases and then conducted clustering analysis to categorize the 700 groups of genes to obtain the eight functional groups. Annotations included checking 701 the constraint score (pLI) from the gnomAD database 68 , identifying whether the genes 702 were reported in previous GWAS on CAD and its risk factors (lipids, diabetes, obesity, 703 blood pressure, coagulation function, and smoking-related phenotypes) using the 704 GWAS Catalog, and checking for the overlap with target genes of enhancers that were 705 significant in previous GWAS on CAD and its risk factors (same as above) using the 706 GeneHancer database, which includes genome-wide enhancers and their target genes 21 . 707 Further analysis involved examining the International Mouse Phenotyping Consortium 708 (IMPC) database to determine if the corresponding genes in knock-out mice are 709 significantly related to phenotypes such as blood pressure, blood glucose and lipid traits. 710 Enrichment analysis for Gene Ontology and Human Phenotype Ontology was 711 performed using g:Profiler 69 to gain insights into the biological processes and human 712 phenotypic abnormalities associated with these genes 22 . We considered statistical 713 significance for the enrichment analysis with a false discovery rate under 0.1.

714 To analyze the functional modules in CAD, we downloaded the human 715 protein-protein interactions (PPIs) from STRING v12.0, comprising 19,622 proteins and 716 6,857,702 interactions. High-confidence PPIs (combined score >700) were extracted for 717 downstream analysis, including 16,185 proteins and 236,000 interactions. To remove 718 bias from hub proteins, we applied the random walk with restart (RWR) algorithm with 719 a restart probability of 0.5. This produced a smoothed network after retaining the top 720 5% predicted edges (n = 6,243,766). We employed the Louvain method ⁷⁰ to decompose

721 the network into different modules. Following algorithm convergence, we obtained 722 1,261 modules with an average size of 13 nodes. Among the 1,261 PPI modules, 46 723 encompassed at least one gene identified by the machine learning analysis. We used 724 g:profiler to determine functional enrichment for each module. Cytoscape software 71 725 was used to visualize the PPI modules.

726

727 **Genetic risk scores**

728 By optimizing the machine learning-based model, the modified HEAL 729 framework can also make a prediction of disease based on the input genome. We call it 730 rare variant-based genetic risk score (RVS) because it only leverages information on 731 rare variants. Using the trained model, we estimated the RVS prediction performance in 732 the validation cohort. We also analyzed the association between RVS and clinical 733 parameters such as vital signs and blood test data in the BBJ data using Pearson's 734 correlation. To investigate the prognostic impact of RVS, we divided the patients into 735 those in the top 5% and those below, then compared their outcome using Kaplan-Meier 736 analysis and a log-rank test. To compare the properties between RVS and the common 737 variant-based polygenic risk score (PRS), GWAS of CAD in BBJ (case 25,668 vs 738 control 141,667) was performed. The individuals included in the GWAS were 739 genotyped using the HumanOmniExpressExome v.1.0/v.1.2 platform (Illumina) or in 740 combination with HumanOmniExpress v.1.0 and Human Exome BeadChip v.1.0/v.1.1 741 (Illumina). For genotype quality control, variants with (1) SNP call rate < 99%, (2) 742 Hardy–Weinberg equilibrium ($P < 1$ *10⁻⁶) and (3) heterozygous counts ≤ 5 were 743 excluded. We performed pre-phasing using Eagle software. Phased haplotypes were 744 imputed to the in-house reference panel from BBJ 11 by minimac3⁷². Variants with low

745 imputation quality $(R^2<0.3)$ were excluded. GWAS was performed by logistic 746 regression implemented in PLINK 2.0 60 with adjustment for age, age², sex and first 10 747 principal components of ancestry. Then PRS of *i*th sample was calculated as follows

$$
PRS_i = \sum_{j=1}^{M} a_{i,j} \beta_j
$$

748 , where M is the number of variants in GWAS, $a_{i,j}$ is the number of effect allele of *j*th 749 variant in *i*th sample, and $β_j$ is the effect size of *j*th variant estimated by GWAS. The 750 number of variants included in the PRS calculation was determined by the pruning and 751 thresholding method 13 . The relationship between RVS and PRS was examined by 752 Pearson's correlation coefficient, both in cases only and across the validation cohort. We 753 then integrated both RVS and PRS by normalizing (mean 0, standard deviation 1) and 754 adding them together to obtain combined risk score (CRS). The predictive performance 755 of each genetic score was estimated on the validation cohort, which was not used in the 756 derivation of the RVS, PRS, or CRS. We used receiver operating characteristics (ROC) 757 to evaluate the predictive performance. To examine whether CRS improves predictive 758 performance compared to conventional PRS, we compared AUROC of PRS and CRS 759 by DeLong's test. We also calculated the area under precision-recall curve (AUPRC) 760 and Nagelkerke's pseudo R^2 metrics. The P values were derived using a 20000 times 761 bootstrap replication method. In all statistical analyses, R software was used and a two-762 sided $P < 0.05$ was considered statistically significant.

763

765 **Reference**

916 Lancet *396*, 1644–1652.

A

B

C

A ROC analysis

